Microsatellite analysis in exfoliated cells from urine sediment. Utility for bladder cancer detection. Comparative study with urinary cytology;Análisis de microsatélites en células exfoliadas del sedimento urinario. Su utilidad para la detección del cáncer vesical. Estudio comparativo con citología urinaria

Actas Urologicas Espanolas

Volumn 27, Issue 8, 2003, Pages 618-628

  Molina Burgos, R ^a,b   Millan Salvador J M ^a   Oltra Soler, J S ^a   Jimenez Cruz J F ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b NONE   (Spain)

Author keywords

Bladder cancer; Cytology; Inestability (MSI); Loss of heterozigosity (LOH); Microsatellite

Indexed keywords

DNA;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; BLADDER CANCER; CANCER DIAGNOSIS; DIAGNOSTIC VALUE; FEMALE; HETEROZYGOSITY LOSS; HISTOLOGY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MICROSATELLITE MARKER; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TRANSURETHRAL RESECTION; URINE CYTOLOGY; URINE SEDIMENT;

EID: 0141961090     PISSN: 02104806     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0210-4806(03)72984-2     Document Type: Article

References (51)

1. GREENLEE RT, MURRIA T, BOLDEN S et al.: Cancer statistics, 2000. CA Cancer J Clin 2000; 50: 7-33.
2. MARTÍNEZ PIÑEIRO JA, MARTÍNEZ PIÑEIRO L. Tumores vesicales. En Tratado de Urología. J.F. Jiménez Cruz, A.L. Rioja Sáez. JR Prous Editores 1993: 1151-1152.
3. HOLMANG S, HEDELIN H, ANDERSTROM C, JOHANSSON SL.: The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J Urol 1995; 153: 1823-1826.
4. WOLF H, KAKIZOE T, SMITH PH et al.: Bladder tumors. Treated natural history. Prog Clin Biol Res 1986; 221: 223-255.
5. PAPANICOLAOU GN, MARSHALL VF.: Urine sediment smears as a diagnostic procedure in cancers of the urinary tract. Science 1945; 101: 519-520.
6. SARNACKI CT, MCCORMACK LJ, KISER WS, HAZARD JB, MC LOUGHLIN TC, BELOVICH DM et al.: Urinary cytology and the clinical diagnosis of the urinary tract malignancy: a clinicpathologic study of 1400 patients. J Urol 1971; 106: 761-764.
7. GUTIÉRREZ BANOS JL, MARTÍN GARCÍA B, DE DIEGO RODRÍGUEZ E et al.: El BTA STAT en el seguimiento del cáncer vesical. Arch Esp de Urología 1999; 52: 856-861.
8. RODRÍGUEZ MARTÍNEZ JJ, ESCAF BARMADAH S, ALLENDE MT et al.: Cuantificación del antígeno tumoral vesical (BTA Trak) y su correlación con el grado y estadio del carcinoma vesical. Arch Esp de Urología 2000; 53: 1-6.
9. WEBER JL, MAY PE.: Abundant class of human DNA polymorphisms which can be typed using the polymerise chain reaction. Am J Hum Genet 1989; 44: 388-396.
10. WEISSENBACH J, GYAPAY G, DIB C et al.: A second-generation linkage map of the human genome. Nature 1992; 359: 794-801.
11. MAO L, LEE DJ, TOCKMAN MS, EROZAN YS, ASKIN F, SIDRANSKY D.: Microsatellite alterations as clonal markers for the detection of human cancer. Proc Natl Acad Sci 1994; 91: 9871-9875.
12. SELLI C, TRAVAGLINI M, DAL CANTO M, PIAZZINI M, FRONTERA S, BARTOLETTI R.: Microsatellite analysis in the detection of bladder carcinoma: a preliminary report. Acta Urol Ital 1999; 13: 117-120.
13. MAO L, SCHOENBERG MP, SCICCHITANO M et al.: Molecular detection of primary bladder cancer by microsatellite analysis. Science 1996; 271: 659-662.
14. CHEN XQ, STROUN M, MAGNENAT JL et al.: Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nat Med 1996; 2: 1033-1035.
15. FUJIWARA Y, CHI DD, WANG H et al.: Plasma DNA microsatellites as tumor-specific markers and indicators of tumor progresión in melanoma patients. Cancer Res 1999; 59: 1567-1571.
16. NAWROZ H, KOCH W, ANKER P et al.: Microsatellite alterations in serum DNA of head and neck cancer patients. Nat Med 1996; 2: 1035-1037.
17. HIBI K, ROBINSON CR, BOOKER S et al.: Molecular detection of genetic alterations in the serum of colorectal cancer patients. Cancer Res 1998; 58: 1405-1407.
18. STEINER G, SCHOENBERG MP, LINN JF et al.: Detection of bladder cancer recurrence by microsatellite analysis of urine. Nat Med 1997; 3: 621-624.
19. CHRISTENSEN M, JENSEN MA, WOLF H, ORNTOFT T et al.: Pronounced microsatellite instability in transitional cell carcinomas from young patients with bladder cancer. Int J Cancer 1998; 79: 396-401.
20. MOURAH S, CUSSENOT O, VIMONT V et al.: Assessment of microsatellite instability in urine in the detection of transitional cell carcinoma of the bladder. Int J Cancer 1998; 79: 629-633.
21. BONNAL C, RAVERY V, TOUBLANC M et al.: Absence of microsatellite instability in transitional cell carcinoma of the bladder. Urology 2000; 55: 287-291.
22. HABUCHI T, DEVLIN J, ELDER PA, KNOWLES MA.: Delailed deletion mapping of chromosome 9p in the bladder cancer: evidence for two tumour suppressor loci. Oncogene 1995; 11: 1671-1674.
23. SHAW ME, KNOWLES MA.: Deletion mapping of chromosome 11 in carcinoma of the bladder. Genes Chromosomes Cancer 1995; 13: 1-8.
24. PRESTI JC Jr, REUTER VE, GALAN T, FAIR WR, CORDON-CARDO C.: Molecular genetic alterations in superficial and locally advanced human bladder cancer. Cancer Res 1991; 51: 5405-5409.
25. MIYAMOTO H, SHUIN T, IWASAKI Y, KUBOTA Y.: Retinoblastoma gene mutations in primary human bladder cancer. Brit J Cancer 1995; 71: 831-835.
26. HABUCHI H, OGAWA O, KAKEHI Y et al.: Alleleic loss of chromosome 17p in urothelial cancer: strong association with invasive phenotype. J Urol 1992; 148: 1595-1599.
27. KNOWLES MA, SHAW ME, PROCTOR AJ.: Deletion mapping of chromosome 8 in cancers of the urinary bladder using restriction fragment length polymorphisms and microsatellite polymorphisms. Oncogene 1993; 8: 1357-1364.
28. POLASCIK TJ, CARINS P, CHANG YH, SCJOENBERG MP, SIDRANSKY D.: Distinct regions of allelic loss on chromosome 4 in human primary bladder carcinoma. Cancer Res 1995; 55: 5396-5399.
29. Pollock PM et al.: Evidence for three tumor suppressor loci on chromosome 9p involved in melanoma development. Cancer Research 2001; 61: 1154-1161.
30. BROWN F.: Examen citológico de la orina. En "Cáncer Superficial de Vejiga": nuevas estrategias diagnósticas y terapéuticas. Clínicals de Urología de Norteamérica 2000; 1.
31. VOGELSTEIN B, FEARRON ER, KERN SE et al.: Allelotype of colorectal carcinomas. Science 1989; 244: 207-211.
32. THORSTENSEN L, QVIST H, NESLAND JM et al.: Allelotype profiles of local recurrences and distant metastases from colorectal-cancer patients. Int J Cancer 1996; 69: 452-456.
33. LININGER R, FUJJI H, MAN YG et al.: Comparison of loss heterozygosity in primary and recurrent ductal carcinoma in situ of the breast. Mol Pathol 1998; 11: 1151-1159.
34. WALSH T, CHAPPELL SA, SHAW JA et al.: Microsatellite instability in ductal carcinoma in situ of the breast. J Pathol 1998; 185: 18-24.
35. TSUCHIYA E, NAKAMURA Y, WENG SY et al.: Allelotype of non-small cell lung carcinoma - comparison between loss heterozygosity in squamous carcinoma and adenocarcinoma. Cancer Res 1992; 52: 2478-2481.
36. SHISEKI M, KOHNO T, ADACHI J et al.: Comparative allelotype of early and advanced stage non-small cell lung carcinoma. Genes Chromosome Cancer 1996; 17: 71-77.
37. NAWROZ H, VAN DER RIET P, HRUBAN RH et al.: Allelotype of head and neck squamous cell carcinoma. Cancer Res 1994; 54: 1152-1155.
38. MORITA R, ISHIKAWA J, TSUTSUMI M et al.: Allelopype of renal cell carcinoma. Cancer Res 1991; 51: 820-823.
39. HEALY E, BELGAID CE, TAKATA M et al.: Allelopyes of cutaneous melanoma and benign melanocytic nevi. Cancer Res 1996; 56: 589-593.
40. PARRELLA P, SIDRANSKY D, MERBS SL.: Allelopype of posterior uveal melanoma: implications for a fiburcated tumor progression. Cancer Res 1999; 59: 3032-3037.
41. SEPIRA D, PARRELLA P, GALLUCCI M et al.: Sensitive detection of transitional cell carcinoma of the bladder by microsatellite analysis of cell exfoliatedin urine. Int J Cancer 2001; 95: 364-369.
42. NEVES M, CIOFU C, LAROUSSERIE F et al.: Prospective evaluation of genetic abnormalities and telomerase expression in exfoliated urinary cells for bladder cancer detection. J Urol 2002; 167: 1276-1281.
43. SOURVINOS G, KAZANIS I, DELAKAS D, CRADINIS A, SPANDIDOS D.: Genetic detection of bladder cancer by microsatellite análisis of p16, RB1 and p53 tumor supresor genes. J Urol 2001; 165: 249-252.
44. BERGER AP, PARSON W, STENZL A, STEINER H, BARTSCH G, KLOCKER H.: Microsatellite alterations in human bladder cancer: detection of tumor cells in urine sediment and tumor tissue. European Urology 2002; 41: 532-539.
45. VON KNOBLOCH R, HEGELE A, BRANDT H, OLBERT P, HEIDENREICH A, HOFMANN R.: Serun DNA and urine DNA. Alterations of urinary transitional cell bladder carcinoma detected by fluorescent microsatellite analysis. Int J Cancer 2001; 94: 67-72.
46. UTTING M, WERNER W, MULLER G, SCHUBERT J, JUNKER K.: A Possible noninvasive method for the detection of bladder cancer in patients: microsatellite analysis of free DNA in urine and blood. Ann NY Acad Sci 2001; 945: 31-35.
47. UTTING M, MULLER G, WERNER W et al.: Detection of tumor genetic alterations of bladder carcinomas in body fluids depends on sample treatment before DNA isolation. Ann NY Acad Sci 2000; 906: 67-71.
48. VAN RHIFN B, LURKIN I, KIRKELS W, VAN DER KWAST T, ZWARTHOFF E.: Microsatellite análisis - DNA test in urine completes with cystoscopy in follow-up of superficial bladder carcinoma. Cancer 2001; 92: 768-775.
49. SHIBATA D, NAVIDI W, SALOVAARA R, LI ZH, AALTONEN AL.: Somatic microsatellite as molecular tumor clocks. Nature (Med) 1996; 2: 676-681.
50. LOTAN Y, ROEHRBORN CG.: Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review an meta-analyses. J Urol 2001; 165: [abstract 680].
51. RUIZ A, PUIG S, LYNCH M, CASTEL T, ESTIVILL X.: Retention of the CDKN2A locus and low prequency of point mutations in primary and metastatic cutaneous malignant melanoma. Int J Cancer 1998; 76: 312-316.